NCT01642589View on ClinicalTrials.gov

Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

January 31, 2013

Study Completion Date

June 30, 2013

Conditions
MeningitisMeningococcal Disease
Interventions
BIOLOGICAL

Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)

0.5 mL, Intramuscular

BIOLOGICAL

Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed

0.5 mL, Intramuscular

Trial Locations (7)

Unknown

Incheon

Gyeonggi-do

Seoul

Seoul

Seoul

Gyeonggi-do

Gangwon Do

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT01642589 - Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea | Biotech Hunter | Biotech Hunter